Search
Search Results
-
A qualitative study of experiences with physical activity among people receiving opioid agonist therapy
BackgroundPhysical or mental health comorbidities are common among people with substance use disorders undergoing opioid agonist therapy. As both a...
-
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner
Aberrant dopaminergic and glutamatergic function, particularly within the striatum and hippocampus, has repeatedly been associated with the...
-
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
Radiotherapy (XRT), a well-known activator of the inflammasome and immune priming, is in part capable of reversing resistance to anti-PD1 treatment....
-
Upregulation of CIRP by its agonist prevents the development of heart failure in myocardial infarction rats
BackgroundDownregulated expression of cold-inducible RNA binding protein (CIRP), a stress-response protein, has been demonstrated in the hearts of...
-
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
Reovirus, a naturally occurring oncolytic virus, initiates the lysis of tumor cells while simultaneously releasing tumor antigens or proapoptotic...
-
TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming
Immune checkpoint inhibitors have revolutionized anti-tumor therapy, notably improving treatment responses in various tumors. However, many patients...
-
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate
STING is a pivotal mediator of effective innate and adaptive anti-tumor immunity; however, intratumoral administration of STING agonists have shown...
-
Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv)
BackgroundSubstance use disorder is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. People with...
-
Trends in smoking during pregnancy stratified by the use of opioid agonist therapy and the contribution of smoking to poor outcome in neonates prenatally exposed to opioid agonist treatment
High rates of cigarette smoking have been observed in pregnant women on opioid agonist therapy (OAT). However, it is unclear if these rates have...
-
Antagonist activation exercises elicit similar post-activation performance enhancement as agonist activities on throwing performance
BackgroundThis study aimed to determine the acute effect of agonist and antagonist conditioning activities (CA) on medicine ball throw performance...
-
Healthy eating among people on opioid agonist therapy: a qualitative study of patients’ experiences and perspectives
People with substance use disorders often have unhealthy diets, high in sweets and processed foods but low in nutritious items like fruits and...
-
Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer
Suppression of the cGAS-STING pathway is an immune escape mechanism in cancer cells. The critical role of this pathway in gastric cancer (GC) is not...
-
Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol
PurposeTo explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and...
-
Effectiveness of GnRH Agonist Short Protocol Versus GnRH Antagonist Protocol in POSEIDON Groups 3 and 4: a Retrospective Cohort Study
The aim of this study is to compare the ART (assisted reproductive technology) outcomes and cancellation rates between GnRH antagonist protocol and...
-
Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapy
Immunotherapy is one of the most promising anti-cancer treatment. It involves activating the host's own immune system to eliminate cancer cells....
-
The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study
IntroductionThe administration of opioids can be followed by enduring neuroplastic changes in the peripheral and central nervous systems. This...
-
Pretreatment with or without GnRH-agonist before frozen–thawed embryo transfer in patients with PCOS: a systematic review and meta-analysis
PurposeThis study was aimed to systematically evaluate the efficacy of artificial cycle-prepared frozen–thawed embryo transfer (FET) with or without...
-
Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
BackgroundAcross different types of oral Opioid Agonist Treatment for people with Opioid Use Disorder, receiving a dose that meets their needs is...
-
Agonist-antagonist muscle strain in the residual limb preserves motor control and perception after amputation
BackgroundElucidating underlying mechanisms in subject-specific motor control and perception after amputation could guide development of advanced...
-
PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats
The increased incidence of hypertension associated with obstructive sleep apnea (OSA) presents significant physical, psychological, and economic...
